Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly (LLY) is following the right approach for the obesity drugs business as it explores multiple ways to address the balance between demand and supply, according to Truist Securities. The ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly (LLY-2.55%) is working to capture as much of that market as it can, and it's probably going to succeed. Here's why. The juggernaut is picking up speed ...

Sales of diabetes-obesity drug Mounjaro could play a big role at Lilly in future years. Photo: Sandy Huffaker for The Washington Post/Getty Images Eli Lilly LLY 0.18 % increase; green up pointing ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor.Clinical trial results from competitors were largely underwhelming, including this week’s ...

Cantor sees Eli Lilly reaching over 85% obesity market share by 2029–2030. Orforglipron lowered A1C by 1.3%–1.6% from baseline in Phase 3 ACHIEVE-1 trial. Historic Summer Setup: 3 "Power ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Eli Lilly, for its part, sells tirzepatide as Mounjaro and Zepbound for diabetes and obesity, respectively. In addition, retatrutide is Lilly’s next-generation weight loss candidate.

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

Novo is up 19% so far this year, while Eli Lilly has gained 33%. The iShares U.S. Pharmaceuticals ETF IHE , an exchange traded fund that tracks U.S. pharma companies, is up 12.5% in 2024.